U.S. Precision Medicine Inc. has announced plans to use artificial intelligence (AI) technology to support work on its small-molecule drug candidate for cancer.

Vrise Therapeutics Inc. has developed and presented a USP1 inhibitor, VRTX-531, for the potential treatment of BRCA1/2-mutated HDR+ breast cancer.

Breast cancer is a heterogenous disease in terms of its prognosis and treatment response. Metabolic reprogramming is a potential therapeutic target because of its repercussion on oncogenesis.

Biotheryx Inc. has gained FDA clearance for its IND application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader.

Hologic Inc. moved to expand its breast surgery line with the acquisition of Endomagnetics Ltd. (Endomag) for a proposed $310 million. Endomag offers a magnetic system that allows precise localization of tumors in the breast and lymph nodes without the use of radioactive materials or wires, enabling greater preservation of healthy tissue. The transaction is expected to close in the second half of 2024.

Poly(ADP-ribose) polymerase 1 (PARP-1) plays a crucial role in DNA repair and represents the pivotal target for first-generation PARP inhibitors.